TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies

Cytokine

Volumn 82, Issue , 2016, Pages 52-57

  Pike, Kelly A ^a   Tremblay, Michel L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

JAK STAT; Leukemia and lymphoma; PTP1B; TC PTP; Tyrosine phosphatase

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PROTEIN KINASE TYK2; PROTEIN TYROSINE PHOSPHATASE 1B; STAT1 PROTEIN; STAT2 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; JANUS KINASE; PTPN1 PROTEIN, HUMAN; PTPN2 PROTEIN, HUMAN; STAT PROTEIN; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; ENZYME INHIBITION; ENZYME REGULATION; FRAMESHIFT MUTATION; GENE SEQUENCE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; LYMPHOMAGENESIS; MARGINAL ZONE LYMPHOMA; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; PATHOGENESIS; PERIPHERAL T CELL LYMPHOMA; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PTPN1 GENE; PTPN2 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T CELL LEUKEMIA; GENETICS; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; PATHOLOGY;

HUMANS; JANUS KINASES; LEUKEMIA; LYMPHOMA; NEOPLASM PROTEINS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84955299618     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.12.025     Document Type: Article

References (58)

1. Mullighan C.G. Genome sequencing of lymphoid malignancies. Blood 2013, 122:3899. December 5.
2. Yui M.A., Rothenberg E.V. Developmental gene networks: a triathlon on the course to T cell identity. Nat. Rev. 2014, 14:529. August.
3. Vainchenker W., Constantinescu S.N. JAK/STAT signaling in hematological malignancies. Oncogene 2013, 32:2601. May 23.
4. Zenatti P.P., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 2011, 43:932. October.
5. Shochat C., et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 2011, 208:901. May 9.
6. O'Shea J.J., et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu. Rev. Med. 2015, 66:311.
7. Andersson E., et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 2015, September 30.
8. Kontro M., et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia 2014, 28:1738. August.
9. Andersson E.I., et al. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013, 3:e168.
10. Rajala H.L., et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013, 121:4541. May 30.
11. Koskela H.L., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. New Engl. J. Med. 2012, 366:1905. May 17.
12. Weniger M.A., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006, 25:2679. April 27.
13. Melzner I., et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005, 105:2535. March 15.
14. Reddy J., et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005, 24:732. January 20.
15. Capello D., et al. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. Hematol. Oncol. 2013, 31:22. March.
16. Brender C., et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005, 19:209. February.
17. Hardy S., Julien S.G., Tremblay M.L. Impact of oncogenic protein tyrosine phosphatases in cancer. Anti-Cancer Agents Med. Chem. 2012, 12:4. January.
18. Andersen J.N., et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 2001, 21:7117. November.
19. Ruela-de-Sousa R.R., Queiroz K.C., Peppelenbosch M.P., Fuhler G.M. Reversible phosphorylation in haematological malignancies: potential role for protein tyrosine phosphatases in treatment?. Biochim. Biophys. Acta 2010, 1806:287. December.
20. Mertins P., et al. Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol. Cell. Proteomics: MCP 2008, 7:1763. September.
21. Feldhammer M., Uetani N., Miranda-Saavedra D., Tremblay M.L. PTP1B: a simple enzyme for a complex world. Crit. Rev. Biochem. Mol. Biol. 2013, 48:430. September-October.
22. Myers M.P., et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 2001, 276:47771. December 21.
23. Lu X., et al. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood 2008, 112:4098. November 15.
24. Heinonen K.M., Dube N., Bourdeau A., Lapp W.S., Tremblay M.L. Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2776. February 21.
25. Grant L., et al. Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide induced inflammation, hyperinsulinemia and endotoxemia through an IL10 STAT3 dependent mechanism. Diabetes 2013, November 1.
26. Pike K.A., et al. Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. Sci. Signal. 2014, 7:ra43. May 6.
27. Woodford-Thomas T.A., Rhodes J.D., Dixon J.E. Expression of a protein tyrosine phosphatase in normal and v-src-transformed mouse 3T3 fibroblasts. J. Cell Biol. 1992, 117:401. April.
28. Brown-Shimer S., Johnson K.A., Hill D.E., Bruskin A.M. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res. 1992, 52:478. January 15.
29. Lessard L., Stuible M., Tremblay M.L. The two faces of PTP1B in cancer. Biochim. Biophys. Acta 2010, 1804:613. March.
30. Julien S.G., et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 2007, 39:338. March.
31. Dube N., et al. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res. 2005, 65:10088. November 1.
32. Gunawardana J., et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat. Genet. 2014, 46:329. April.
33. Kay N.E., Pittner B.T. IL-4 biology: impact on normal and leukemic CLL B cells. Leukemia Lymphoma 2003, 44:897. June.
34. Simoncic P.D., McGlade C.J., Tremblay M.L. PTP1B and TC-PTP: novel roles in immune-cell signaling. Can. J. Physiol. Pharmacol. 2006, 84:667. July.
35. Bussieres-Marmen S., et al. Characterization of PTPN2 and its use as a biomarker. Methods (San Diego, Calif) 2014, 65:239. January 15.
36. Tiganis T., Bennett A.M., Ravichandran K.S., Tonks N.K. Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol. Cell. Biol. 1998, 18:1622. March.
37. Tiganis T., Flint A.J., Adam S.A., Tonks N.K. Association of the T-cell protein tyrosine phosphatase with nuclear import factor p97. J. Biol. Chem. 1997, 272:21548. August 22.
38. You-Ten K.E., et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 1997, 186:683. August 29.
39. Heinonen K.M., et al. T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease. Blood 2004, 103:3457. May 1.
40. Wiede F., et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Investig. 2011, 121:4758. December.
41. Doody K.M., Bourdeau A., Tremblay M.L. T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol. Rev. 2009, 228:325. March.
42. Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr. Biol. 2002, 12:446. March 19.
43. Bourdeau A., et al. TC-PTP-deficient bone marrow stromal cells fail to support normal B lymphopoiesis due to abnormal secretion of interferon-{gamma}. Blood 2007, 109:4220. May 15.
44. Wiede F., La Gruta N.L., Tiganis T. PTPN2 attenuates T-cell lymphopenia-induced proliferation. Nat. Commun. 2014, 5:3073.
45. Kleppe M., et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 2010, 42:530. June.
46. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. 2008, 8:380. May.
47. Kleppe M., et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 2011, 117:7090. June 30.
48. Asnafi V., et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood 2004, 104:4173. December 15.
49. Ferrando A.A., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75. February.
50. Soulier J., et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005, 106:274. July 1.
51. Ferrando A.A., et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004, 363:535. February 14.
52. Kees U.R., et al. Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG). Leukemia 2003, 17:887. May.
53. Berger R., et al. t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 2003, 17:1851. September.
54. Roberts C.W., Shutter J.R., Korsmeyer S.J. Hox11 controls the genesis of the spleen. Nature 1994, 368:747. April 21.
55. De Keersmaecker K., et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat. Med. 2010, 16:1321. November.
56. Kleppe M., et al. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma. Haematologica 2011, 96:1723. November.
57. Young R.M., Polsky A., Refaeli Y. TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas. Blood 2009, 114:5016. December 3.
58. Arimura Y., Yagi J. Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells. Sci. Signal. 2010, 3:rs1.